<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Knisely A</submitter><funding>NCI NIH HHS</funding><funding>University of Texas MD Anderson Cancer Center</funding><pagination>326.e1-326.e13</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11961129</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>231(3)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Surgical site infection is one of the most common complications of gynecologic cancer surgery. Current guidelines recommend the administration of cefazolin preoperatively to reduce surgical site infection rates for patients undergoing clean-contaminated surgeries such as hysterectomy.&lt;h4>Objective&lt;/h4>To evaluate the impact of a quality improvement project adding metronidazole to cefazolin for antibiotic prophylaxis on surgical site infection rate for women undergoing gynecologic surgery at a comprehensive cancer center.&lt;h4>Study design&lt;/h4>This retrospective, single-center cohort study included patients who underwent surgery in the gynecologic oncology department from May 2017 to June 2023. Patients with penicillin allergies and those undergoing concomitant bowel resect</pubmed_abstract><journal>American journal of obstetrics and gynecology</journal><pubmed_title>Metronidazole and cefazolin vs cefazolin alone for surgical site infection prophylaxis in gynecologic surgery at a comprehensive cancer center.</pubmed_title><pmcid>PMC11961129</pmcid><funding_grant_id>T32 CA101642</funding_grant_id><funding_grant_id>P30 CA016672</funding_grant_id><funding_grant_id>CA101642</funding_grant_id><pubmed_authors>Taylor JS</pubmed_authors><pubmed_authors>Schmeler KM</pubmed_authors><pubmed_authors>Chisholm G</pubmed_authors><pubmed_authors>Knisely A</pubmed_authors><pubmed_authors>Iniesta MD</pubmed_authors><pubmed_authors>Marten CA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Metronidazole and cefazolin vs cefazolin alone for surgical site infection prophylaxis in gynecologic surgery at a comprehensive cancer center.</name><description>&lt;h4>Background&lt;/h4>Surgical site infection is one of the most common complications of gynecologic cancer surgery. Current guidelines recommend the administration of cefazolin preoperatively to reduce surgical site infection rates for patients undergoing clean-contaminated surgeries such as hysterectomy.&lt;h4>Objective&lt;/h4>To evaluate the impact of a quality improvement project adding metronidazole to cefazolin for antibiotic prophylaxis on surgical site infection rate for women undergoing gynecologic surgery at a comprehensive cancer center.&lt;h4>Study design&lt;/h4>This retrospective, single-center cohort study included patients who underwent surgery in the gynecologic oncology department from May 2017 to June 2023. Patients with penicillin allergies and those undergoing concomitant bowel resect</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2025-07-14T03:02:26.206Z</modification><creation>2025-07-14T03:02:26.206Z</creation></dates><accession>S-EPMC11961129</accession><cross_references><pubmed>38599478</pubmed><doi>10.1016/j.ajog.2024.03.043</doi></cross_references></HashMap>